Articles citing this paper
Pharmaceuticals and the consumer movement: the ambivalences of ‘patient power'
Hans Lofgren
28(2) pp.228 - 237
17 articles found in Crossref database.
Pharmaceuticalization of Society in Context: Theoretical, Empirical and Health Dimensions
Abraham John
Sociology. 2010 44(4). p.603
In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK
Jones Kathryn
Sociology of Health & Illness. 2008 30(6). p.929
The effects of an apparent breach of therapeutic regulations on consumers: the Pan Pharmaceuticals recall
Blasche Roswitha E.C.,
Worsley Anthony, Lawrence Mark
Critical Public Health. 2008 18(3). p.367
Assessing Stakeholder Opinion on Relations between Cancer Patient Groups and Pharmaceutical Companies in Europe
Leto di Priolo Susanna,
Fehervary Andras,
Riggins Phil, Redmond Kathy
The Patient: Patient-Centered Outcomes Research. 2012 5(2). p.127
Government Influence on Patient Organizations
Van de Bovenkamp Hester M., Trappenburg Margo J.
Health Care Analysis. 2011 19(4). p.329
Patient organizations in Finland: increasing numbers and great variation
Toiviainen Hanna K.,
Vuorenkoski Lauri H., Hemminki Elina K.
Health Expectations. 2010 13(3). p.221
Public views on priority setting for High Cost Medications in public hospitals in Australia
Gallego Gisselle,
Taylor Susan J.,
McNeill Paul, Brien Jo‐anne E.
Health Expectations. 2007 10(3). p.224
Patient advocacy in newborn screening: Continuities and discontinuities
Paul Diane B.
American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2008 148C(1). p.8
Patient participation in collective healthcare decision making: the Dutch model
Van De Bovenkamp Hester M.,
Trappenburg Margo J., Grit Kor J.
Health Expectations. 2010 13(1). p.73
The Role of Patient Advocacy Organizations in Shaping Genomic Science
Koay Pei P., Sharp Richard R.
Annual Review of Genomics and Human Genetics. 2013 14(1). p.579
Understanding Users in the ‘Field’ of Medications
Ballantyne Peri
Pharmacy. 2016 4(2). p.19
On the prohibition of conflicts of interest in pharmaceutical regulation: Precautionary limits and permissive challenges. A commentary on Sismondo (66:9, 2008, 1909–14) and O'Donovan and Lexchin
Abraham John
Social Science & Medicine. 2010 70(5). p.648
Ethical Issues in Community and Patient Stakeholder–Engaged Health Research (2023)
Chasing cures: Rewards and risks for rare disease patient organisations involved in research
Pinto Deirdre,
Martin Dominique, Chenhall Richard
BioSocieties. 2018 13(1). p.123
Pharmaceutical Policy in Hong Kong: Defining an Evolving Area of Study
Chan Benjamin Tak-Yuen
SSRN Electronic Journal. 2009
Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK
Rickard Emily,
Ozieranski Piotr, Mulinari Shai
Health Policy. 2019 123(12). p.1244
WHO's web-based public hearings: hijacked by pharma?
Wibulpolprasert Suwit,
Moosa Sheena,
Satyanarayana K,
Samarage Sarath, Tangcharoensathien Viroj
The Lancet. 2007 370(9601). p.1754
